PRVB - Provention Bio launches first-in-human PRV-101 study in coxsackievirus B

Provention Bio (PRVB) has initiated PROVENT (PROtocol for coxsackievirus VaccinE in healthy voluNTeers), a first-in-human study of its polyvalent inactivated coxsackievirus B ((CVB)) vaccine candidate, PRV-101.PRV-101 is being developed for the prevention of acute CVB infection and the potential delay or prevention of type 1 diabetes (T1D) and celiac disease. The study's primary endpoint is the safety of two dose levels of PRV-101 in healthy adult volunteers. Tolerability and immunogenicity will also be evaluated. Results are expected in H2 2021. CVB is potentially serious infection that damages insulin-producing cells and gut-lining cells, triggering a T-cell immune response which causes autoimmunity in predisposed individuals.

For further details see:

Provention Bio launches first-in-human PRV-101 study in coxsackievirus B